We are live on ! Find out more
KPRX icon

Kiora Pharmaceuticals
KPRX

11 hedge funds and large institutions have $1.22M invested in Kiora Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more ownership

Funds ownership: 0.01% → 0.02% (+0%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

9% less capital invested

Capital invested by funds: $1.34M → $1.22M (-$124K)

42% less funds holding

Funds holding: 19 → 11 (-8)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 8

Holders
11
Holders Change
-8
Holders Change %
-42.11%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
2
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$448K
2
UBS Group
UBS Group
Switzerland
+$31.6K

Top Sellers

Rank Fund Capital Flow
1
SCA
Sassicaia Capital Advisers
New York
-$56K
2
TCM
Tuttle Capital Management
Connecticut
-$41K
3
XT
XTX Topco
Cayman Islands
-$31K
4
CS
Credit Suisse
Switzerland
-$23K
5
HF
HRT Financial
New York
-$22K
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
1
Geode Capital Management
Massachusetts
$791K +$448K +795 +120%
Vanguard Group
2
Vanguard Group
Pennsylvania
$229K – – –
T. Rowe Price Associates
3
T. Rowe Price Associates
Maryland
$77K – – –
Jane Street
4
Jane Street
New York
$47K -$5.64K -10 -10%
BlackRock
5
BlackRock
New York
$32K – – –
UBS Group
6
UBS Group
Switzerland
$31K +$31.6K +56 +5,600%
US Bancorp
7
US Bancorp
Minnesota
$4K – – –
Osaic Holdings
8
Osaic Holdings
Arizona
$3K – – –
TRCT
9
Tower Research Capital (TRC)
New York
$1K -$20.9K -37 -97%
Morgan Stanley
10
Morgan Stanley
New York
$1K – – –
SCA
11
Sassicaia Capital Advisers
New York
– -$56K -69 Closed
TCM
12
Tuttle Capital Management
Connecticut
– -$41K -50 Closed
XT
13
XTX Topco
Cayman Islands
– -$31K -39 Closed
CS
14
Credit Suisse
Switzerland
– -$23K -28 Closed
HF
15
HRT Financial
New York
– -$22K -28 Closed
Royal Bank of Canada
16
Royal Bank of Canada
Ontario, Canada
– -$4K -5 Closed
NFSG
17
Newbridge Financial Services Group
Florida
– -$2K -3 Closed
SFP
18
Sterling Financial Planning
New Jersey
– -$3K -3 Closed

KPRX Hedge Fund Activity: Q4 2021 in Review

11 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q4 2021, worth a combined $1.22M — down 9.3% from $1.34M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of KPRX and 0 opened new positions — a net loss of 8 holders — while 2 trimmed existing stakes and 2 added.

The largest buyer was Geode Capital Management, adding an estimated $448K. The largest seller was Sassicaia Capital Advisers, exiting entirely with an estimated $56K sold.

  • 11 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q4 2021, down from 19 in Q3 2021.
  • Funds reported $1.22M of Kiora Pharmaceuticals stock for Q4 2021, down 9.3% quarter-over-quarter.
  • 0 funds opened new Kiora Pharmaceuticals positions in Q4 2021 and 8 closed out, a net change of -8 holders.
  • The largest Kiora Pharmaceuticals buyer in Q4 2021 was Geode Capital Management, an estimated $448K added.
  • The largest Kiora Pharmaceuticals seller in Q4 2021 was Sassicaia Capital Advisers, an estimated $56K sold.

Based on aggregated 13F filings for Q4 2021.